Nasdaq1mon
AIM ImmunoTech Inc. Announces Dosing of First Subject in Phase 2 Trial of Ampligen Combined with Imfinzi for Late-Stage Pancreatic Cancer
AIM ImmunoTech Inc. announced that the first subject has been dosed in Phase 2 of its clinical trial called DURIPANC, which studies its drug Ampligen (rintatolimod) in combination with AstraZeneca ...
Morningstar1mon
AIM Doses First New Subject in Phase 2 Study of Ampligen and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer
(“AIM” or the “Company”) today announced that the first new subject has been dosed in Phase 2 of the Phase 1b/2 clinical trial involving AIM’s Ampligen (rintatolimod) and AstraZeneca’s ...
Alzamend Neuro announces initiation date of Phase II trial of AL001
Alzamend Neuro (ALZN) announced its plans to initiate a highly anticipated phase II clinical study of AL001 for treatment of patients with ...
Clinical Trials Arena on MSN10d
iOnctura doses first subject in Phase II uveal melanoma treatment trial
Onctura has dosed the first subject in the Phase II OCULE-01 trial of oral roginolisib in individuals with metastatic uveal ...
Hosted on MSN1mon
Vaxcyte enters final stage of Phase II pneumococcal vaccine trial in infants
The ongoing stage two aims to assess ... enters final stage of Phase II pneumococcal vaccine trial in infants" was originally created and published by Clinical Trials Arena, a GlobalData owned ...
Oragenics, Inc. Submits Investigator’s Brochure for Phase II Clinical Trial of ONP-002 in Mild Traumatic Brain Injury (mTBI)
Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing innovative treatments for concussion and brain-related health conditions, today announced the submission of its Investigator’s ...
Alzamend Neuro announces initiation of Phase II trial of AL001
Alzamend Neuro (ALZN) announced its plans to initiate a highly anticipated phase II clinical study of AL001 for treatment of patients with PTSD ...
Mena FN1mon
AIM Doses First New Subject In Phase 2 Study Of Ampligen And Imfinzi As A Potential Combination Therapy For Late-Stage Pancreatic Cancer
Up to 25 patients are expected to be enrolled in the Phase 2 portion of DURIPANC. AIM CEO Thomas K ... with broad spectrum activity in clinical trials for globally important cancers, viral ...